These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36762206)

  • 41. Amythiamicin D and related thiopeptides as inhibitors of the bacterial elongation factor EF-Tu: modification of the amino acid at carbon atom C2 of ring C dramatically influences activity.
    Gross S; Nguyen F; Bierschenk M; Sohmen D; Menzel T; Antes I; Wilson DN; Bach T
    ChemMedChem; 2013 Dec; 8(12):1954-62. PubMed ID: 24106106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
    Zhang G; Li S; Wang F; Jones AC; Goldberg AFG; Lin B; Virgil S; Stoltz BM; Deshaies RJ; Chou TF
    Eur J Med Chem; 2021 Mar; 213():113148. PubMed ID: 33476933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Designed mono- and di-covalent inhibitors trap modeled functional motions for Trypanosoma cruzi proline racemase in crystallography.
    Amaral PA; Autheman D; de Melo GD; Gouault N; Cupif JF; Goyard S; Dutra P; Coatnoan N; Cosson A; Monet D; Saul F; Haouz A; Uriac P; Blondel A; Minoprio P
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006853. PubMed ID: 30372428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanistic basis of the inhibition of type II dehydroquinase by (2S)- and (2R)-2-benzyl-3-dehydroquinic acids.
    Lence E; Tizón L; Otero JM; Peón A; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; González-Bello C
    ACS Chem Biol; 2013 Mar; 8(3):568-77. PubMed ID: 23198883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Irreversible inhibition of type I dehydroquinase by substrates for type II dehydroquinase.
    Bello CG; Harris JM; Manthey MK; Coggins JR; Abell C
    Bioorg Med Chem Lett; 2000 Mar; 10(5):407-9. PubMed ID: 10743936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reducing the Flexibility of Type II Dehydroquinase for Inhibition: A Fragment-Based Approach and Molecular Dynamics Study.
    Peón A; Robles A; Blanco B; Convertino M; Thompson P; Hawkins AR; Caflisch A; González-Bello C
    ChemMedChem; 2017 Sep; 12(18):1512-1524. PubMed ID: 28791799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In silico identification of irreversible cathepsin B inhibitors as anti- cancer agents: virtual screening, covalent docking analysis and molecular dynamics simulations.
    Sbongile M; Soliman ME
    Comb Chem High Throughput Screen; 2015; 18(4):399-410. PubMed ID: 25747438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
    Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
    J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rational structural modification of the isatin scaffold to develop new and potent antimicrobial agents targeting bacterial peptidoglycan glycosyltransferase.
    Wang Y; Liang Z; Zheng Y; Leung AS; Yan SC; So PK; Leung YC; Wong WL; Wong KY
    RSC Adv; 2021 May; 11(29):18122-18130. PubMed ID: 35480164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Planning Implications Related to Sterilization-Sensitive Science Investigations Associated with Mars Sample Return (MSR).
    Velbel MA; Cockell CS; Glavin DP; Marty B; Regberg AB; Smith AL; Tosca NJ; Wadhwa M; Kminek G; Meyer MA; Beaty DW; Carrier BL; Haltigin T; Hays LE; Agee CB; Busemann H; Cavalazzi B; Debaille V; Grady MM; Hauber E; Hutzler A; McCubbin FM; Pratt LM; Smith CL; Summons RE; Swindle TD; Tait KT; Udry A; Usui T; Westall F; Zorzano MP
    Astrobiology; 2022 Jun; 22(S1):S112-S164. PubMed ID: 34904892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Covalent modification of aromatase by a radiolabeled irreversible inhibitor.
    Snider CE; Brueggemeier RW
    J Steroid Biochem; 1985 Mar; 22(3):325-30. PubMed ID: 3990283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
    Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
    J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L.
    Ehmke V; Winkler E; Banner DW; Haap W; Schweizer WB; Rottmann M; Kaiser M; Freymond C; Schirmeister T; Diederich F
    ChemMedChem; 2013 Jun; 8(6):967-75. PubMed ID: 23658062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Turnover-dependent covalent inactivation of Staphylococcus aureus coenzyme A-disulfide reductase by coenzyme A-mimetics: mechanistic and structural insights.
    Wallace BD; Edwards JS; Wallen JR; Moolman WJ; van der Westhuyzen R; Strauss E; Redinbo MR; Claiborne A
    Biochemistry; 2012 Oct; 51(39):7699-711. PubMed ID: 22954034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: an essential enzyme for mycobacterial survival inside macrophages.
    Abuhammad A; Fullam E; Lowe ED; Staunton D; Kawamura A; Westwood IM; Bhakta S; Garner AC; Wilson DL; Seden PT; Davies SG; Russell AJ; Garman EF; Sim E
    PLoS One; 2012; 7(12):e52790. PubMed ID: 23285185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Irreversible inhibition of delta 5-3-oxosteroid isomerase by 2-substituted progesterones.
    Penning TM
    Biochem J; 1985 Mar; 226(2):469-76. PubMed ID: 3838891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state.
    Steuber H; Zentgraf M; La Motta C; Sartini S; Heine A; Klebe G
    J Mol Biol; 2007 May; 369(1):186-97. PubMed ID: 17418233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
    Jöst C; Nitsche C; Scholz T; Roux L; Klein CD
    J Med Chem; 2014 Sep; 57(18):7590-9. PubMed ID: 25148591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An explorative study on
    Azam MA; Saha N; Jupudi S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):45-54. PubMed ID: 31162992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.